<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35459141</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A.</ArticleTitle><Pagination><StartPage>98</StartPage><MedlinePgn>98</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">98</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-022-02446-6</ELocationID><Abstract><AbstractText>Neurodegenerative diseases are a group of disorders characterized by progressive loss of certain populations of neurons, which eventually lead to dysfunction. These diseases include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Immune pathway dysregulation is one of the common features of neurodegeneration. Recently, there is growing interest in the specific role of T helper Th 17 cells and Interleukin-17A (IL-17A), the most important cytokine of Th 17 cells, in the pathogenesis of the central nervous system (CNS) of neurodegenerative diseases. In the present study, we summarized current knowledge about the function of Th17/IL-17A, the physiology of Th17/IL-17A in diseases, and the contribution of Th17/IL-17A in AD, PD, and ALS. We also update the findings on IL-17A-targeting drugs as potentially immunomodulatory therapeutic agents for neurodegenerative diseases. Although the specific mechanism of Th17/IL-17A in this group of diseases is still controversial, uncovering the molecular pathways of Th17/IL-17A in neurodegeneration allows the identification of suitable targets to modulate these cellular processes. Therapeutics targeting IL-17A might represent potentially novel anti-neurodegeneration drugs.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Jiajia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue Xiang 37#, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Management Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Management Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chengcheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Periodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xueping</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-4290-7404</Identifier><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue Xiang 37#, Chengdu, Sichuan, China. chenxueping0606@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2017YFC09007703</GrantID><Agency>National key Research and development program of China</Agency><Country/></Grant><Grant><GrantID>2020YJ0281</GrantID><Agency>science and technology planning project in Sichuan Province</Agency><Country/></Grant><Grant><GrantID>ZYJC18038</GrantID><Agency>1&#xb7;3&#xb7;5 project for disciplines of excellence West China Hospital Sichuan University</Agency><Country/></Grant><Grant><GrantID>2019-112</GrantID><Agency>cadres health care project in Sichuan Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508717">IL17A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="Y">Interleukin-17</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058504" MajorTopicYN="Y">Th17 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">IL-17A</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">TH17</Keyword><Keyword MajorTopicYN="N">Targeted therapy</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35459141</ArticleId><ArticleId IdType="pmc">PMC9034482</ArticleId><ArticleId IdType="doi">10.1186/s12974-022-02446-6</ArticleId><ArticleId IdType="pii">10.1186/s12974-022-02446-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration. Immunity. 2019;50(4):955&#x2013;974. doi: 10.1016/j.immuni.2019.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.016</ArticleId><ArticleId IdType="pmc">PMC6822103</ArticleId><ArticleId IdType="pubmed">30995509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353(6301):777&#x2013;783. doi: 10.1126/science.aag2590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag2590</ArticleId><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Liu X, Zhong Y. Interleukin-17A: the key cytokine in neurodegenerative diseases. Front Aging Neurosci. 2020;12:566922. doi: 10.3389/fnagi.2020.566922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.566922</ArticleId><ArticleId IdType="pmc">PMC7550684</ArticleId><ArticleId IdType="pubmed">33132897</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123&#x2013;1132. doi: 10.1038/ni1254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1254</ArticleId><ArticleId IdType="pubmed">16200070</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133&#x2013;1141. doi: 10.1038/ni1261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1261</ArticleId><ArticleId IdType="pmc">PMC1618871</ArticleId><ArticleId IdType="pubmed">16200068</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Hall JA, Kroehling L, et al. Serum Amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease [published correction appears in Cell. 2020;183(7):2036&#x2013;9] Cell. 2020;180(1):79&#x2013;91.e16. doi: 10.1016/j.cell.2019.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.11.026</ArticleId><ArticleId IdType="pmc">PMC7039443</ArticleId><ArticleId IdType="pubmed">31866067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235&#x2013;238. doi: 10.1038/nature04753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04753</ArticleId><ArticleId IdType="pubmed">16648838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441(7090):231&#x2013;234. doi: 10.1038/nature04754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04754</ArticleId><ArticleId IdType="pubmed">16648837</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24(2):179&#x2013;189. doi: 10.1016/j.immuni.2006.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.01.001</ArticleId><ArticleId IdType="pubmed">16473830</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967&#x2013;974. doi: 10.1038/ni1488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1488</ArticleId><ArticleId IdType="pubmed">17581537</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y, Chang SH, Martinez GJ, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 2009;30(4):576&#x2013;587. doi: 10.1016/j.immuni.2009.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.02.007</ArticleId><ArticleId IdType="pmc">PMC2705871</ArticleId><ArticleId IdType="pubmed">19362022</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirota K, Duarte JH, Veldhoen M, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 2011;12(3):255&#x2013;263. doi: 10.1038/ni.1993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1993</ArticleId><ArticleId IdType="pmc">PMC3040235</ArticleId><ArticleId IdType="pubmed">21278737</ArticleId></ArticleIdList></Reference><Reference><Citation>Komuczki J, Tuzlak S, Friebel E, et al. Fate-mapping of GM-CSF expression identifies a discrete subset of inflammation-driving T helper cells regulated by cytokines IL-23 and IL-1&#x3b2;. Immunity. 2019;50(5):1289&#x2013;1304.e6. doi: 10.1016/j.immuni.2019.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.04.006</ArticleId><ArticleId IdType="pubmed">31079916</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol. 2009;10(3):314&#x2013;324. doi: 10.1038/ni.1698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1698</ArticleId><ArticleId IdType="pmc">PMC2945605</ArticleId><ArticleId IdType="pubmed">19182808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121&#x2013;1133. doi: 10.1016/j.cell.2006.07.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.07.035</ArticleId><ArticleId IdType="pubmed">16990136</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008;28(1):29&#x2013;39. doi: 10.1016/j.immuni.2007.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2007.11.016</ArticleId><ArticleId IdType="pmc">PMC2587175</ArticleId><ArticleId IdType="pubmed">18164222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Wen Z, Darnell JE., Jr Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264(5155):95&#x2013;98. doi: 10.1126/science.8140422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8140422</ArticleId><ArticleId IdType="pubmed">8140422</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice [published correction appears in J Immunol. 2015;194(7):3526] J Immunol. 1998;161(9):4652&#x2013;4660.</Citation><ArticleIdList><ArticleId IdType="pubmed">9794394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XO, Panopoulos AD, Nurieva R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007;282(13):9358&#x2013;9363. doi: 10.1074/jbc.C600321200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C600321200</ArticleId><ArticleId IdType="pubmed">17277312</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26(3):371&#x2013;381. doi: 10.1016/j.immuni.2007.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2007.02.009</ArticleId><ArticleId IdType="pubmed">17363300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-&#x3b2; signalling. Nature. 2010;467(7318):967&#x2013;971. doi: 10.1038/nature09447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09447</ArticleId><ArticleId IdType="pmc">PMC3108066</ArticleId><ArticleId IdType="pubmed">20962846</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9(6):650&#x2013;657. doi: 10.1038/ni.1613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1613</ArticleId><ArticleId IdType="pubmed">18454150</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892&#x2013;906. doi: 10.1016/j.immuni.2019.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.021</ArticleId><ArticleId IdType="pmc">PMC6474359</ArticleId><ArticleId IdType="pubmed">30995505</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvier E, Luciani MF, Matt&#xe9;i MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150(12):5445&#x2013;5456.</Citation><ArticleIdList><ArticleId IdType="pubmed">8390535</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffen SL. Life before seventeen: cloning of the IL-17 receptor. J Immunol. 2011;187(9):4389&#x2013;4391. doi: 10.4049/jimmunol.1102576.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102576</ArticleId><ArticleId IdType="pmc">PMC4824884</ArticleId><ArticleId IdType="pubmed">22013204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system [published correction appears in Nat Rev Immunol. 2010;10(8):611] [published correction appears in Nat Rev Immunol. 2010;10(7):following 489] Nat Rev Immunol. 2010;10(7):479&#x2013;489. doi: 10.1038/nri2800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2800</ArticleId><ArticleId IdType="pubmed">20559326</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(9):e60. doi: 10.1038/emi.2013.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2013.58</ArticleId><ArticleId IdType="pmc">PMC3820987</ArticleId><ArticleId IdType="pubmed">26038490</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev. 2010;21(6):413&#x2013;423. doi: 10.1016/j.cytogfr.2010.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2010.10.002</ArticleId><ArticleId IdType="pmc">PMC3008409</ArticleId><ArticleId IdType="pubmed">21074482</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatfield JK, Brown MA. Group 3 innate lymphoid cells accumulate and exhibit disease-induced activation in the meninges in EAE. Cell Immunol. 2015;297(2):69&#x2013;79. doi: 10.1016/j.cellimm.2015.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2015.06.006</ArticleId><ArticleId IdType="pubmed">26163773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosmi L, Maggi L, Santarlasci V, Liotta F, Annunziato F. T helper cells plasticity in inflammation. Cytometry A. 2014;85(1):36&#x2013;42. doi: 10.1002/cyto.a.22348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.22348</ArticleId><ArticleId IdType="pubmed">24009159</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosmi L, Santarlasci V, Maggi L, Liotta F, Annunziato F. Th17 plasticity: pathophysiology and treatment of chronic inflammatory disorders. Curr Opin Pharmacol. 2014;17:12&#x2013;16. doi: 10.1016/j.coph.2014.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2014.06.004</ArticleId><ArticleId IdType="pubmed">24980083</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311&#x2013;321. doi: 10.1111/j.1365-2567.2009.03240.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2009.03240.x</ArticleId><ArticleId IdType="pmc">PMC2826676</ArticleId><ArticleId IdType="pubmed">20409152</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585&#x2013;600. doi: 10.1038/nri3707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3707</ArticleId><ArticleId IdType="pmc">PMC4281037</ArticleId><ArticleId IdType="pubmed">25145755</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol. 2015;195(3):780&#x2013;788. doi: 10.4049/jimmunol.1500909.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1500909</ArticleId><ArticleId IdType="pmc">PMC4507294</ArticleId><ArticleId IdType="pubmed">26188072</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond RA, Lionakis MS. Organ-specific mechanisms linking innate and adaptive antifungal immunity. Semin Cell Dev Biol. 2019;89:78&#x2013;90. doi: 10.1016/j.semcdb.2018.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2018.01.008</ArticleId><ArticleId IdType="pmc">PMC6054575</ArticleId><ArticleId IdType="pubmed">29366628</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik S, Bouladoux N, Linehan JL, et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature. 2015;520(7545):104&#x2013;108. doi: 10.1038/nature14052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14052</ArticleId><ArticleId IdType="pmc">PMC4667810</ArticleId><ArticleId IdType="pubmed">25539086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485&#x2013;498. doi: 10.1016/j.cell.2009.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.09.033</ArticleId><ArticleId IdType="pmc">PMC2796826</ArticleId><ArticleId IdType="pubmed">19836068</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P, Monin L, Castillo P, et al. Intestinal interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation. Immunity. 2016;44(3):659&#x2013;671. doi: 10.1016/j.immuni.2016.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.02.007</ArticleId><ArticleId IdType="pmc">PMC4794750</ArticleId><ArticleId IdType="pubmed">26982366</ArticleId></ArticleIdList></Reference><Reference><Citation>Phuna ZX, Madhavan P. A closer look at the mycobiome in Alzheimer&#x2019;s disease: fungal species, pathogenesis and transmission. Eur J Neurosci. 2022;55(5):1291&#x2013;1321. doi: 10.1111/ejn.15599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.15599</ArticleId><ArticleId IdType="pubmed">35048439</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012;181(1):8&#x2013;18. doi: 10.1016/j.ajpath.2012.03.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.03.044</ArticleId><ArticleId IdType="pubmed">22640807</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22(8):993&#x2013;1005. doi: 10.1517/13543784.2013.806483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.2013.806483</ArticleId><ArticleId IdType="pubmed">23731078</ArticleId></ArticleIdList></Reference><Reference><Citation>Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A Inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534&#x2013;2548. doi: 10.1056/NEJMoa1505066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1505066</ArticleId><ArticleId IdType="pubmed">26699169</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647&#x2013;1656. doi: 10.1002/art.24568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24568</ArticleId><ArticleId IdType="pubmed">19479869</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavelka K, Chon Y, Newmark R, Lin SL, Baumgartner S, Erondu N. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol. 2015;42(6):912&#x2013;919. doi: 10.3899/jrheum.141271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.141271</ArticleId><ArticleId IdType="pubmed">25877498</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Chu Y, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1472&#x2013;1483. doi: 10.1002/art.24499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24499</ArticleId><ArticleId IdType="pubmed">19404966</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med. 2009;15(5):199&#x2013;207. doi: 10.1016/j.molmed.2009.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2009.03.002</ArticleId><ArticleId IdType="pubmed">19362058</ArticleId></ArticleIdList></Reference><Reference><Citation>Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9(6):641&#x2013;649. doi: 10.1038/ni.1610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1610</ArticleId><ArticleId IdType="pmc">PMC2597394</ArticleId><ArticleId IdType="pubmed">18454151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8(5):500&#x2013;508. doi: 10.1038/nm0502-500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0502-500</ArticleId><ArticleId IdType="pubmed">11984595</ArticleId></ArticleIdList></Reference><Reference><Citation>Schofield C, Fischer SK, Townsend MJ, et al. Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis. Bioanalysis. 2016;8(22):2317&#x2013;2327. doi: 10.4155/bio-2016-0207.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/bio-2016-0207</ArticleId><ArticleId IdType="pubmed">27620302</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis [published correction appears in Immunology. 2008;125(3):438] Immunology. 2008;125(2):161&#x2013;169. doi: 10.1111/j.1365-2567.2008.02837.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2008.02837.x</ArticleId><ArticleId IdType="pmc">PMC2561132</ArticleId><ArticleId IdType="pubmed">18397264</ArticleId></ArticleIdList></Reference><Reference><Citation>Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009;132(Pt 12):3329&#x2013;3341. doi: 10.1093/brain/awp289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp289</ArticleId><ArticleId IdType="pubmed">19933767</ArticleId></ArticleIdList></Reference><Reference><Citation>Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009;65(5):499&#x2013;509. doi: 10.1002/ana.21652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21652</ArticleId><ArticleId IdType="pubmed">19475668</ArticleId></ArticleIdList></Reference><Reference><Citation>Setiadi AF, Abbas AR, Jeet S, et al. IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2019;332:147&#x2013;154. doi: 10.1016/j.jneuroim.2019.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2019.04.011</ArticleId><ArticleId IdType="pubmed">31034962</ArticleId></ArticleIdList></Reference><Reference><Citation>Waisman A, Hauptmann J, Regen T. The role of IL-17 in CNS diseases. Acta Neuropathol. 2015;129(5):625&#x2013;637. doi: 10.1007/s00401-015-1402-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1402-7</ArticleId><ArticleId IdType="pubmed">25716179</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert J, Closhen D, Croxford A, et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. 2010;24(4):1023&#x2013;1034. doi: 10.1096/fj.09-141978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.09-141978</ArticleId><ArticleId IdType="pubmed">19940258</ArticleId></ArticleIdList></Reference><Reference><Citation>Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1173&#x2013;1175. doi: 10.1038/nm1651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1651</ArticleId><ArticleId IdType="pmc">PMC5114125</ArticleId><ArticleId IdType="pubmed">17828272</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahmasebinia F, Pourgholaminejad A. The role of Th17 cells in auto-inflammatory neurological disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):408&#x2013;416. doi: 10.1016/j.pnpbp.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2017.07.023</ArticleId><ArticleId IdType="pubmed">28760387</ArticleId></ArticleIdList></Reference><Reference><Citation>Prajeeth CK, Kronisch J, Khorooshi R, et al. Effectors of Th1 and Th17 cells act on astrocytes and augment their neuroinflammatory properties. J Neuroinflamm. 2017;14(1):204. doi: 10.1186/s12974-017-0978-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0978-3</ArticleId><ArticleId IdType="pmc">PMC5644084</ArticleId><ArticleId IdType="pubmed">29037246</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010;24(4):641&#x2013;651. doi: 10.1016/j.bbi.2010.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.01.014</ArticleId><ArticleId IdType="pubmed">20138983</ArticleId></ArticleIdList></Reference><Reference><Citation>Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233&#x2013;240. doi: 10.1084/jem.20041257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041257</ArticleId><ArticleId IdType="pmc">PMC2212798</ArticleId><ArticleId IdType="pubmed">15657292</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172(1):146&#x2013;155. doi: 10.2353/ajpath.2008.070690.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.070690</ArticleId><ArticleId IdType="pmc">PMC2189615</ArticleId><ArticleId IdType="pubmed">18156204</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal BM. Th17 cells in autoimmune demyelinating disease. Semin Immunopathol. 2010;32(1):71&#x2013;77. doi: 10.1007/s00281-009-0186-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-009-0186-z</ArticleId><ArticleId IdType="pmc">PMC2874248</ArticleId><ArticleId IdType="pubmed">20195867</ArticleId></ArticleIdList></Reference><Reference><Citation>Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177(1):566&#x2013;573. doi: 10.4049/jimmunol.177.1.566.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.1.566</ArticleId><ArticleId IdType="pubmed">16785554</ArticleId></ArticleIdList></Reference><Reference><Citation>Havrdov&#xe1; E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016;263(7):1287&#x2013;1295. doi: 10.1007/s00415-016-8128-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8128-x</ArticleId><ArticleId IdType="pubmed">27142710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Zhang S, Zhang X, Zhang X, Dong H, Qian Y. IL-17A is implicated in lipopolysaccharide-induced neuroinflammation and cognitive impairment in aged rats via microglial activation. J Neuroinflamm. 2015;12:165. doi: 10.1186/s12974-015-0394-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0394-5</ArticleId><ArticleId IdType="pmc">PMC4572693</ArticleId><ArticleId IdType="pubmed">26373740</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristiano C, Volpicelli F, Lippiello P, et al. Neutralization of IL-17 rescues amyloid-&#x3b2;-induced neuroinflammation and memory impairment. Br J Pharmacol. 2019;176(18):3544&#x2013;3557. doi: 10.1111/bph.14586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14586</ArticleId><ArticleId IdType="pmc">PMC6715610</ArticleId><ArticleId IdType="pubmed">30673121</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer A, Marxreiter F, Krach F, et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson&#x2019;s disease [published correction appears in Cell Stem Cell. 2019 Jun 6;24(6):1006] Cell Stem Cell. 2018;23(1):123&#x2013;131.e6. doi: 10.1016/j.stem.2018.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2018.06.015</ArticleId><ArticleId IdType="pubmed">29979986</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Qiu AW, Huang Y, et al. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease. Brain Behav Immun. 2019;81:630&#x2013;645. doi: 10.1016/j.bbi.2019.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2019.07.026</ArticleId><ArticleId IdType="pubmed">31351185</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Huang Y, Cao BB, Qiu YH, Peng YP. Th17 cells induce dopaminergic neuronal death via LFA-1/ICAM-1 interaction in a mouse model of parkinson&#x2019;s disease. Mol Neurobiol. 2017;54(10):7762&#x2013;7776. doi: 10.1007/s12035-016-0249-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0249-9</ArticleId><ArticleId IdType="pubmed">27844285</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Akg&#xfc;n K, Ziemssen T, Kipp M, G&#xfc;nther R, Hermann A. Interleukin-17 and Th17 lymphocytes directly impair motoneuron survival of wildtype and FUS-ALS mutant human iPSCs. Int J Mol Sci. 2021;22(15):8042. doi: 10.3390/ijms22158042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158042</ArticleId><ArticleId IdType="pmc">PMC8348495</ArticleId><ArticleId IdType="pubmed">34360808</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan XZ, Lai L, Ao Q, Tian XH, Zhang YH. Interleukin-17A in Alzheimer's disease: recent advances and controversies. Curr Neuropharmacol. 2022;20(2):372&#x2013;383. doi: 10.2174/1570159X19666210823110004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X19666210823110004</ArticleId><ArticleId IdType="pubmed">34429057</ArticleId></ArticleIdList></Reference><Reference><Citation>Taipa R, das Neves SP, Sousa AL, et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline. Neurobiol Aging. 2019;76:125&#x2013;132. doi: 10.1016/j.neurobiolaging.2018.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.12.019</ArticleId><ArticleId IdType="pubmed">30711675</ArticleId></ArticleIdList></Reference><Reference><Citation>Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012;69(10):1318&#x2013;1325. doi: 10.1001/archneurol.2012.1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.1282</ArticleId><ArticleId IdType="pmc">PMC6287606</ArticleId><ArticleId IdType="pubmed">22801742</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Chen-Plotkin A, Grossman M, et al. Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology. 2010;75(23):2079&#x2013;2086. doi: 10.1212/WNL.0b013e318200d78d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318200d78d</ArticleId><ArticleId IdType="pmc">PMC2995537</ArticleId><ArticleId IdType="pubmed">21048198</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenaro E, Pietronigro E, Della Bianca V, et al. Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med. 2015;21(8):880&#x2013;886. doi: 10.1038/nm.3913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3913</ArticleId><ArticleId IdType="pubmed">26214837</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA. IFN-&#x3b3; Production by amyloid &#x3b2;-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J Immunol. 2013;190(5):2241&#x2013;2251. doi: 10.4049/jimmunol.1200947.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1200947</ArticleId><ArticleId IdType="pubmed">23365075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi Shahrokhi V, Ravari A, Mirzaei T, Zare-Bidaki M, Asadikaram G, Arababadi MK. IL-17A and IL-23: plausible risk factors to induce age-associated inflammation in Alzheimer's disease. Immunol Invest. 2018;47(8):812&#x2013;822. doi: 10.1080/08820139.2018.1504300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2018.1504300</ArticleId><ArticleId IdType="pubmed">30081688</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Wen S, Li G, Wang D. Hypoxia enhances stimulating effect of amyloid beta peptide (25&#x2013;35) for interleukin 17 and T helper lymphocyte subtype 17 upregulation in cultured peripheral blood mononuclear cells. Microbiol Immunol. 2009;53(5):281&#x2013;286. doi: 10.1111/j.1348-0421.2009.00120.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.2009.00120.x</ArticleId><ArticleId IdType="pubmed">19457169</ArticleId></ArticleIdList></Reference><Reference><Citation>Machhi J, Yeapuri P, Lu Y, et al. CD4+ effector T cells accelerate Alzheimer&#x2019;s disease in mice. J Neuroinflamm. 2021;18(1):272. doi: 10.1186/s12974-021-02308-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02308-7</ArticleId><ArticleId IdType="pmc">PMC8603581</ArticleId><ArticleId IdType="pubmed">34798897</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Ju T, Wang T, et al. Decreased Netrin-1 and correlated Th17/Tregs balance disorder in A&#x3b2;1&#x2013;42 induced alzheimer's disease model rats. Front Aging Neurosci. 2019;11:124. doi: 10.3389/fnagi.2019.00124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00124</ArticleId><ArticleId IdType="pmc">PMC6548067</ArticleId><ArticleId IdType="pubmed">31191297</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopp RC, Baumann KK, Wilson ML, Banks WA, Erickson MA. Amyloid Beta pathology exacerbates weight loss and brain cytokine responses following low-dose lipopolysaccharide in aged female Tg2576 mice. Int J Mol Sci. 2022;23(4):2377. doi: 10.3390/ijms23042377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23042377</ArticleId><ArticleId IdType="pmc">PMC8879430</ArticleId><ArticleId IdType="pubmed">35216491</ArticleId></ArticleIdList></Reference><Reference><Citation>Milovanovic J, Arsenijevic A, Stojanovic B, et al. Interleukin-17 in chronic inflammatory neurological diseases. Front Immunol. 2020;11:947. doi: 10.3389/fimmu.2020.00947.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00947</ArticleId><ArticleId IdType="pmc">PMC7283538</ArticleId><ArticleId IdType="pubmed">32582147</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhang M, Liu H. LncRNA17A regulates autophagy and apoptosis of SH-SY5Y cell line as an in vitro model for Alzheimer's disease. Biosci Biotechnol Biochem. 2019;83(4):609&#x2013;621. doi: 10.1080/09168451.2018.1562874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09168451.2018.1562874</ArticleId><ArticleId IdType="pubmed">30652945</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Lu H, Yang S, et al. Salidroside attenuates cognitive dysfunction in senescence-accelerated mouse prone 8 (SAMP8) mice and modulates inflammation of the gut-brain axis. Front Pharmacol. 2020;11:568423. doi: 10.3389/fphar.2020.568423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.568423</ArticleId><ArticleId IdType="pmc">PMC7759146</ArticleId><ArticleId IdType="pubmed">33362539</ArticleId></ArticleIdList></Reference><Reference><Citation>Derkow K, Kr&#xfc;ger C, Dembny P, Lehnardt S. Microglia induce neurotoxic IL-17+ &#x3b3;&#x3b4; T cells dependent on TLR2, TLR4, and TLR9 activation. PLoS ONE. 2015;10(8):e0135898. doi: 10.1371/journal.pone.0135898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0135898</ArticleId><ArticleId IdType="pmc">PMC4545749</ArticleId><ArticleId IdType="pubmed">26288016</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Wu Z, Zeng F, et al. Systemic exposure to lipopolysaccharide from porphyromonas gingivalis induces bone loss-correlated Alzheimer's disease-like pathologies in middle-aged mice. J Alzheimers Dis. 2020;78(1):61&#x2013;74. doi: 10.3233/JAD-200689.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-200689</ArticleId><ArticleId IdType="pubmed">32925065</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP. Th17 cell-mediated neuroinflammation is involved in neurodegeneration of ab1-42-induced Alzheimer's disease model rats. PLoS ONE. 2013;8:e75786. doi: 10.1371/journal.pone.0075786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075786</ArticleId><ArticleId IdType="pmc">PMC3790825</ArticleId><ArticleId IdType="pubmed">24124514</ArticleId></ArticleIdList></Reference><Reference><Citation>St-Amour I, Bosoi CR, Par&#xe9; I, et al. Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer's disease. J Neuroinflamm. 2019;16(1):3. doi: 10.1186/s12974-018-1380-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1380-5</ArticleId><ArticleId IdType="pmc">PMC6320637</ArticleId><ArticleId IdType="pubmed">30611289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lempri&#xe8;re S. T cells on patrol in Alzheimer disease. Nat Rev Neurol. 2020;16(3):128&#x2013;129. doi: 10.1038/s41582-020-0317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0317-7</ArticleId><ArticleId IdType="pubmed">31988485</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M, Calabrese E, Marventano I, et al. Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer's disease. Brain Behav Immun. 2011;25(3):539&#x2013;547. doi: 10.1016/j.bbi.2010.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.004</ArticleId><ArticleId IdType="pubmed">21167930</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberstein TJ, Taha L, Spitzer P, et al. Imbalance of circulating Th17 and regulatory T cells in Alzheimer's disease: a case control study. Front Immunol. 2018;9:1213. doi: 10.3389/fimmu.2018.01213.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01213</ArticleId><ArticleId IdType="pmc">PMC5994416</ArticleId><ArticleId IdType="pubmed">29915582</ArticleId></ArticleIdList></Reference><Reference><Citation>Saksida T, Koprivica I, Vuji&#x10d;i&#x107; M, et al. Impaired IL-17 production in gut-residing immune cells of 5xFAD mice with Alzheimer's Disease pathology. J Alzheimers Dis. 2018;61(2):619&#x2013;630. doi: 10.3233/JAD-170538.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170538</ArticleId><ArticleId IdType="pubmed">29254086</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus RM, Higgins SC, Mills KH, Lynch MA. Respiratory infection promotes T cell infiltration and amyloid-&#x3b2; deposition in APP/PS1 mice. Neurobiol Aging. 2014;35(1):109&#x2013;121. doi: 10.1016/j.neurobiolaging.2013.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.025</ArticleId><ArticleId IdType="pubmed">23993702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahuja M, Buabeid M, Abdel-Rahman E, et al. Immunological alteration &amp; toxic molecular inductions leading to cognitive impairment &amp; neurotoxicity in transgenic mouse model of Alzheimer's disease. Life Sci. 2017;177:49&#x2013;59. doi: 10.1016/j.lfs.2017.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2017.03.004</ArticleId><ArticleId IdType="pubmed">28286225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J, Liu J, Qu Q, Zhao X, Zhang J. JKAP, Th1 cells, and Th17 cells are dysregulated and inter-correlated, among them JKAP and Th17 cells relate to cognitive impairment progression in Alzheimer's disease patients [published online ahead of print, 2021 Sep 30] Ir J Med Sci. 2021 doi: 10.1007/s11845-021-02749-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-021-02749-2</ArticleId><ArticleId IdType="pubmed">34595688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang X, Yang X, Yang X, Xue J, Yang Y. Ganoderic acid A to alleviate neuroinflammation of Alzheimer's disease in mice by regulating the imbalance of the Th17/Tregs axis. J Agric Food Chem. 2021;69(47):14204&#x2013;14214. doi: 10.1021/acs.jafc.1c06304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.1c06304</ArticleId><ArticleId IdType="pubmed">34798773</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Qi Z, Qiao B, Lv Z, Hao Y, Li H. Oxymatrine can attenuate pathological deficits of Alzheimer's disease mice through regulation of neuroinflammation. J Neuroimmunol. 2019;334:576978. doi: 10.1016/j.jneuroim.2019.576978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2019.576978</ArticleId><ArticleId IdType="pubmed">31177033</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis A, Siegl S, Fendt M, et al. Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease. Redox Biol. 2017;12:843&#x2013;853. doi: 10.1016/j.redox.2017.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.04.024</ArticleId><ArticleId IdType="pmc">PMC5406548</ArticleId><ArticleId IdType="pubmed">28448946</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama H. Anti-interleukin-17A and anti-interleukin-23 antibodies may be effective against Alzheimer's disease: role of neutrophils in the pathogenesis. Brain Behav. 2020;10(1):e01504. doi: 10.1002/brb3.1504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.1504</ArticleId><ArticleId IdType="pmc">PMC6955921</ArticleId><ArticleId IdType="pubmed">31849180</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciani DJ. Alzheimer's disease vaccine development: a new strategy focusing on immune modulation. J Neuroimmunol. 2015;287:54&#x2013;63. doi: 10.1016/j.jneuroim.2015.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2015.08.008</ArticleId><ArticleId IdType="pubmed">26439962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubick N, Flournoy PCH, Enciu AM, Manda G, Mickael ME. Drugs modulating CD4+ T cells blood-brain barrier interaction in Alzheimer's disease. Pharmaceutics. 2020;12(9):880. doi: 10.3390/pharmaceutics12090880.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12090880</ArticleId><ArticleId IdType="pmc">PMC7558445</ArticleId><ArticleId IdType="pubmed">32948022</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Kou J, Lalonde R, Fukuchi KI. Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer's disease. Brain Behav Immun. 2017;65:262&#x2013;273. doi: 10.1016/j.bbi.2017.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.05.012</ArticleId><ArticleId IdType="pmc">PMC5537015</ArticleId><ArticleId IdType="pubmed">28526436</ArticleId></ArticleIdList></Reference><Reference><Citation>Tfilin M, Turgeman G. Interleukine-17 administration modulates adult hippocampal neurogenesis and improves spatial learning in mice. J Mol Neurosci. 2019;69(2):254&#x2013;263. doi: 10.1007/s12031-019-01354-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-019-01354-4</ArticleId><ArticleId IdType="pubmed">31254254</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol. 2005;62(3):353&#x2013;357. doi: 10.1001/archneur.62.3.353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.3.353</ArticleId><ArticleId IdType="pubmed">15767499</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011;26(6):1049&#x2013;1055. doi: 10.1002/mds.23732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23732</ArticleId><ArticleId IdType="pubmed">21626550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896&#x2013;912. doi: 10.1016/S0140-6736(14)61393-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61393-3</ArticleId><ArticleId IdType="pubmed">25904081</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehay B, Bourdenx M, Gorry P, et al. Targeting &#x3b1;-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015;14(8):855&#x2013;866. doi: 10.1016/S1474-4422(15)00006-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00006-X</ArticleId><ArticleId IdType="pmc">PMC5217462</ArticleId><ArticleId IdType="pubmed">26050140</ArticleId></ArticleIdList></Reference><Reference><Citation>More SV, Kumar H, Kim IS, Song SY, Choi DK. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm. 2013;2013:952375. doi: 10.1155/2013/952375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/952375</ArticleId><ArticleId IdType="pmc">PMC3712244</ArticleId><ArticleId IdType="pubmed">23935251</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord. 2004;10(Suppl 1):S3&#x2013;S7. doi: 10.1016/j.parkreldis.2004.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2004.01.005</ArticleId><ArticleId IdType="pubmed">15109580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kustrimovic N, Comi C, Magistrelli L, et al. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-na&#xef;ve and drug-treated patients. J Neuroinflamm. 2018;15(1):205. doi: 10.1186/s12974-018-1248-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1248-8</ArticleId><ArticleId IdType="pmc">PMC6044047</ArticleId><ArticleId IdType="pubmed">30001736</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa F, Kuriyama N, Nakagawa M, Imanishi J. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr Gerontol Int. 2012;12(1):102&#x2013;107. doi: 10.1111/j.1447-0594.2011.00740.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1447-0594.2011.00740.x</ArticleId><ArticleId IdType="pubmed">21929737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DA, Kannarkat GT, Cintron AF, et al. LRRK2 levels in immune cells are increased in Parkinson's disease. NPJ Parkinsons Dis. 2017;3:11. doi: 10.1038/s41531-017-0010-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-017-0010-8</ArticleId><ArticleId IdType="pmc">PMC5459798</ArticleId><ArticleId IdType="pubmed">28649611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Qi B, Xu W, et al. Clinical correlation of peripheral CD4+-cell sub-sets, their imbalance and Parkinson's disease. Mol Med Rep. 2015;12(4):6105&#x2013;6111. doi: 10.3892/mmr.2015.4136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2015.4136</ArticleId><ArticleId IdType="pubmed">26239429</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Li B, Li L, Zhang H. The clinical significance of the imbalance of Th17 and Treg cells and their related cytokines in peripheral blood of Parkinson's disease patients. Int J Clin Exp Med. 2016;9:17946&#x2013;17951.</Citation></Reference><Reference><Citation>Cen L, Yang C, Huang S, et al. Peripheral lymphocyte subsets as a marker of Parkinson's disease in a Chinese population. Neurosci Bull. 2017;33(5):493&#x2013;500. doi: 10.1007/s12264-017-0163-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-017-0163-9</ArticleId><ArticleId IdType="pmc">PMC5636734</ArticleId><ArticleId IdType="pubmed">28791571</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Guo C, Zhu J, et al. Increased levels of pro-inflammatory and anti-inflammatory cellular responses in Parkinson's disease patients: search for a disease indicator. Med Sci Monit. 2017;23:2972&#x2013;2978. doi: 10.12659/msm.904240.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/msm.904240</ArticleId><ArticleId IdType="pmc">PMC5484607</ArticleId><ArticleId IdType="pubmed">28624842</ArticleId></ArticleIdList></Reference><Reference><Citation>Storelli E, Cassina N, Rasini E, Marino F, Cosentino M. Do Th17 lymphocytes and IL-17 contribute to Parkinson's disease? A systematic review of available evidence. Front Neurol. 2019;10:13. doi: 10.3389/fneur.2019.00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00013</ArticleId><ArticleId IdType="pmc">PMC6353825</ArticleId><ArticleId IdType="pubmed">30733703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha NP, Assis F, Scalzo PL, et al. Reduced activated T lymphocytes (CD4+CD25+) and plasma levels of cytokines in Parkinson's disease. Mol Neurobiol. 2018;55(2):1488&#x2013;1497. doi: 10.1007/s12035-017-0404-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0404-y</ArticleId><ArticleId IdType="pubmed">28176275</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;lvarez-Luqu&#xed;n DD, Arce-Sillas A, Leyva-Hern&#xe1;ndez J, et al. Regulatory impairment in untreated Parkinson's disease is not restricted to Tregs: other regulatory populations are also involved. J Neuroinflamm. 2019;16(1):212. doi: 10.1186/s12974-019-1606-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1606-1</ArticleId><ArticleId IdType="pmc">PMC6849192</ArticleId><ArticleId IdType="pubmed">31711508</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Li Y, Peng H, et al. Targeted exosome coating gene-chem nanocomplex as "nanoscavenger" for clearing &#x3b1;-synuclein and immune activation of Parkinson's disease. Sci Adv. 2020;6(50):eaba3967. doi: 10.1126/sciadv.aba3967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aba3967</ArticleId><ArticleId IdType="pmc">PMC7732192</ArticleId><ArticleId IdType="pubmed">33310840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S210&#x2013;S212. doi: 10.1016/S1353-8020(11)70065-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(11)70065-7</ArticleId><ArticleId IdType="pubmed">22166438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57(2):176&#x2013;179. doi: 10.1002/ana.20369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20369</ArticleId><ArticleId IdType="pubmed">15668963</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Zhai XR, Du ZS, et al. Dopamine receptor D2 on CD4+ T cells is protective against neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Brain Behav Immun. 2021;98:110&#x2013;121. doi: 10.1016/j.bbi.2021.08.220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.08.220</ArticleId><ArticleId IdType="pubmed">34403737</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgueta D, Contreras F, Prado C, et al. Dopamine receptor D3 expression is altered in CD4+ T cells from Parkinson's disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model. Front Immunol. 2019;10:981. doi: 10.3389/fimmu.2019.00981.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00981</ArticleId><ArticleId IdType="pmc">PMC6504698</ArticleId><ArticleId IdType="pubmed">31118938</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf) 2012;76(3):315&#x2013;325. doi: 10.1111/j.1365-2265.2011.04261.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.2011.04261.x</ArticleId><ArticleId IdType="pubmed">21995874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi JH, Chen J, Cantorna MT. Vitamin D regulation of immune function in the gut: why do T cells have vitamin D receptors? Mol Aspects Med. 2012;33(1):77&#x2013;82. doi: 10.1016/j.mam.2011.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2011.10.014</ArticleId><ArticleId IdType="pmc">PMC3781946</ArticleId><ArticleId IdType="pubmed">22079836</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients. 2015;7(4):3011&#x2013;3021. doi: 10.3390/nu7043011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu7043011</ArticleId><ArticleId IdType="pmc">PMC4425186</ArticleId><ArticleId IdType="pubmed">25912039</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol. 2010;184(5):2261&#x2013;2271. doi: 10.4049/jimmunol.0901852.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901852</ArticleId><ArticleId IdType="pmc">PMC2824790</ArticleId><ArticleId IdType="pubmed">20118279</ArticleId></ArticleIdList></Reference><Reference><Citation>Prots I, Winner B. Th17 cells: a promising therapeutic target for Parkinson's disease? Expert Opin Ther Targets. 2019;23(4):309&#x2013;314. doi: 10.1080/14728222.2019.1590336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2019.1590336</ArticleId><ArticleId IdType="pubmed">30871383</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng YK, Wu QL, Peng YW, et al. Oral P gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice. J Neuroinflamm. 2020;17(1):347. doi: 10.1186/s12974-020-02027-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-02027-5</ArticleId><ArticleId IdType="pmc">PMC7677837</ArticleId><ArticleId IdType="pubmed">33213462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Cao Z, Ma H, et al. Auricular vagus nerve stimulation exerts antiinflammatory effects and immune regulatory function in a 6-OHDA model of Parkinson's disease. Neurochem Res. 2018;43(11):2155&#x2013;2164. doi: 10.1007/s11064-018-2639-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-018-2639-z</ArticleId><ArticleId IdType="pubmed">30311182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KH, Lee SY, Shin J, Hwang JT, Jeon HN, Bae H. Dose-dependent neuroprotective effect of standardized bee venom phospholipase A2 against MPTP-induced Parkinson's disease in mice. Front Aging Neurosci. 2019;11:80. doi: 10.3389/fnagi.2019.00080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00080</ArticleId><ArticleId IdType="pmc">PMC6462482</ArticleId><ArticleId IdType="pubmed">31024294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Zhuang J, Cai P, Li L, Wang R, Chen Z. JKAP relates to disease risk, severity, and Th1 and Th17 differentiation in Parkinson's disease. Ann Clin Transl Neurol. 2021;8(9):1786&#x2013;1795. doi: 10.1002/acn3.51420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51420</ArticleId><ArticleId IdType="pmc">PMC8419400</ArticleId><ArticleId IdType="pubmed">34289265</ArticleId></ArticleIdList></Reference><Reference><Citation>Aftanas LI, Gevorgyan MM, Zhanaeva SY, et al. Therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) on neuroinflammation and neuroplasticity in patients with Parkinson's disease: a placebo-controlled study. Bull Exp Biol Med. 2018;165(2):195&#x2013;199. doi: 10.1007/s10517-018-4128-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10517-018-4128-4</ArticleId><ArticleId IdType="pubmed">29923005</ArticleId></ArticleIdList></Reference><Reference><Citation>MacMahon Copas AN, McComish SF, Fletcher JM, Caldwell MA. The pathogenesis of Parkinson's disease: a complex interplay between astrocytes, microglia, and T lymphocytes? Front Neurol. 2021;12:666737. doi: 10.3389/fneur.2021.666737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.666737</ArticleId><ArticleId IdType="pmc">PMC8189423</ArticleId><ArticleId IdType="pubmed">34122308</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Cao Y, Chen R, et al. HMGB1 A box protects neurons by potently inhibiting both microglia and T cell-mediated inflammation in a mouse Parkinson's disease model. Clin Sci (Lond) 2020;134(15):2075&#x2013;2090. doi: 10.1042/CS20200553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20200553</ArticleId><ArticleId IdType="pubmed">32706028</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016;167(6):1469&#x2013;1480.e12. doi: 10.1016/j.cell.2016.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.11.018</ArticleId><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui G, Qin X, Wu L, et al. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest. 2011;121(2):658&#x2013;670. doi: 10.1172/JCI42974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI42974</ArticleId><ArticleId IdType="pmc">PMC3026720</ArticleId><ArticleId IdType="pubmed">21266776</ArticleId></ArticleIdList></Reference><Reference><Citation>Klotz L, Burgdorf S, Dani I, et al. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity [published correction appears in J Exp Med. 2009 Dec 21;206(13):3159. Novak, Natalija [corrected to Nowak, Nina]] J Exp Med. 2009;206(10):2079&#x2013;2089. doi: 10.1084/jem.20082771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20082771</ArticleId><ArticleId IdType="pmc">PMC2757877</ArticleId><ArticleId IdType="pubmed">19737866</ArticleId></ArticleIdList></Reference><Reference><Citation>Carta AR. PPAR-&#x3b3;: therapeutic prospects in Parkinson's disease. Curr Drug Targets. 2013;14(7):743&#x2013;751. doi: 10.2174/1389450111314070004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450111314070004</ArticleId><ArticleId IdType="pubmed">23469878</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Rombos A, Nikolaou C, et al. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol Scand. 2010;122(6):425&#x2013;429. doi: 10.1111/j.1600-0404.2010.01333.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2010.01333.x</ArticleId><ArticleId IdType="pubmed">20219021</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M, Piancone F, Tortorella P, et al. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin Immunol. 2013;148(1):79&#x2013;88. doi: 10.1016/j.clim.2013.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2013.04.010</ArticleId><ArticleId IdType="pubmed">23665549</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, G&#xfc;nther R, Akg&#xfc;n K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):5941. doi: 10.1038/s41598-020-62756-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62756-8</ArticleId><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Chattopadhay M, La Cava A, et al. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflamm. 2010;7:76. doi: 10.1186/1742-2094-7-76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-76</ArticleId><ArticleId IdType="pmc">PMC2992053</ArticleId><ArticleId IdType="pubmed">21062492</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Feng W, Ou R, et al. Evidence for peripheral immune activation in Parkinson's disease. Front Aging Neurosci. 2021;13:617370. doi: 10.3389/fnagi.2021.617370.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.617370</ArticleId><ArticleId IdType="pmc">PMC8119625</ArticleId><ArticleId IdType="pubmed">33994989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>